Variation in initiating secondary prevention after myocardial infarction by hospitals and physicians, 1997 through 2004

Pharmacoepidemiology and Drug Safety

Volumn 20, Issue 10, 2011, Pages 1088-1097

  Margulis, Andrea V ^a,b   Choudhry, Niteesh K ^a   Dormuth, Colin R ^c   Schneeweiss, Sebastian ^a  

^a BRIGHAM AND WOMEN S HOSPITAL   (United States)

^b HARVARD SCHOOL OF PUBLIC HEALTH   (United States)

^c UNIVERSITY OF BRITISH COLUMBIA   (Canada)

Author keywords

Angiotensin converting enzyme inhibitors; Beta blockers; Myocardial infarction; Prescribing preference; Secondary cardiovascular prevention; Statins

Indexed keywords

ANGIOTENSIN 2 RECEPTOR ANTAGONIST; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; DIPEPTIDYL CARBOXYPEPTIDASE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR;

ACUTE HEART INFARCTION; ADULT; AGED; ARTICLE; CLINICAL DECISION MAKING; COLOMBIA; FEMALE; HOSPITAL DISCHARGE; HOSPITALIZATION; HUMAN; LENGTH OF STAY; MAJOR CLINICAL STUDY; MALE; PHYSICIAN; PRESCRIPTION; PRIORITY JOURNAL; SECONDARY PREVENTION; TREATMENT INDICATION;

ADRENERGIC BETA-ANTAGONISTS; ADULT; AGE FACTORS; AGED; AGED, 80 AND OVER; ANGIOTENSIN II TYPE 1 RECEPTOR BLOCKERS; ANGIOTENSIN-CONVERTING ENZYME INHIBITORS; BRITISH COLUMBIA; COHORT STUDIES; DRUG THERAPY, COMBINATION; FEMALE; HOSPITALS; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; MALE; MIDDLE AGED; MYOCARDIAL INFARCTION; PHYSICIAN'S PRACTICE PATTERNS; PHYSICIANS; SECONDARY PREVENTION; TIME FACTORS; YOUNG ADULT;

EID: 80053236909     PISSN: 10538569     EISSN: 10991557     Source Type: Journal    
DOI: 10.1002/pds.2144     Document Type: Article

References (31)

1. Tu JV, Naylor CD, Austin P. Temporal changes in the outcomes of acute myocardial infarction in Ontario, 1992-1996. CMAJ 1999; 161: 1257-1261.
2. Pilote L, Lavoie F, Ho V, Eisenberg MJ. Changes in the treatment and outcomes of acute myocardial infarction in Quebec, 1988-1995. CMAJ 2000; 163: 31-36.
3. Setoguchi S, Glynn RJ, Avorn J, et al. Improvements in long-term mortality after myocardial infarction and increased use of cardiovascular drugs after discharge: a 10-year trend analysis. J Am Coll Cardiol 2008; 51: 1247-1254.
4. Ryan TJ, Anderson JL, Antman EM, et al. ACC/AHA guidelines for the management of patients with acute myocardial infarction. A report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Committee on Management of Acute Myocardial Infarction). J Am Coll Cardiol 1996; 28: 1328-1428. S0735109796003920 [pii]
5. Antman EM, Anbe DT, Armstrong PW, et al. ACC/AHA guidelines for the management of patients with ST-elevation myocardial infarction-executive summary: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Writing Committee to Revise the 1999 Guidelines for the Management of Patients With Acute Myocardial Infarction). Circulation 2004; 110: 588-636.
6. Armstrong PW, Bogaty P, Buller C, et al. The 2004 ACC/AHA guidelines: a perspective and adaptation for Canada by the Canadian Cardiovascular Society Working Group. Can J Cardiol 2004; 20: 1075-1079.
7. Ryan TJ, Antman EM, Brooks NH, et al. 1999 update: ACC/AHA Guidelines for the Management of Patients with Acute Myocardial Infarction: Executive Summary and Recommendations: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Committee on Management of Acute Myocardial Infarction). Circulation 1999; 100: 1016-1030.
8. Quan H, Cujec B, Jin Y, Johnson D. Acute myocardial infarction in Alberta: temporal changes in outcomes, 1994 to 1999. Can J Cardiol 2004; 20: 213-219.
9. Setoguchi S, Glynn RJ, Avorn J, Levin R, Winkelmayer WC. Ten-year trends of cardiovascular drug use after myocardial infarction among community-dwelling persons ≥65years of age. Am J Cardiol 2007; 100: 1061-1067.
10. Yarzebski J, Granillo E, Spencer FA, et al. Changing trends (1986-2003) in the use of lipid lowering medication in patients hospitalized with acute myocardial infarction: a community-based perspective. Int J Cardiol 2009; 132: 66-74. S0167-5273(07)01971-7 [pii] 10.1016/j.ijcard.2007.10.055
11. Yan AT, Yan RT, Tan M, et al. Optimal medical therapy at discharge in patients with acute coronary syndromes: temporal changes, characteristics, and 1-year outcome. Am Heart J 2007; 154: 1108-1115.
12. Gnavi R, Migliardi A, Demaria M, Petrelli A, Caprioglio A, Costa G. Statins prescribing for the secondary prevention of ischaemic heart disease in Torino, Italy. A case of ageism and social inequalities. Eur J Public Health 2007; 17: 492-496. ckm005 [pii] 10.1093/eurpub/ckm005 [doi]
13. Kulik A, Brookhart MA, Levin R, Ruel M, Solomon DH, Choudhry NK.. Impact of statin use on outcomes after coronary artery bypass graft surgery. Circulation 2008; 118: 1785-1792. CIRCULATIONAHA.108.799445 [pii] 10.1161/CIRCULATIONAHA.108.799445 [doi]
14. Canadian Institute for Health Information, Physicians in Canada: Fee-for-Service Utilization, 2005-2006. CIHI:Ottawa, 2008.
15. Schneeweiss S, Walker AM, Glynn RJ, Maclure M, Dormuth C, Soumerai SB. Outcomes of reference pricing for angiotensin-converting-enzyme inhibitors. N Engl J Med 2002; 346: 822-829. 10.1056/NEJMsa003087 346/11/822 [pii]
16. Brookhart MA, Patrick AR, Schneeweiss S, et al. Physician follow-up and provider continuity are associated with long-term medication adherence: a study of the dynamics of statin use. Arch Intern Med 2007; 167: 847-852.
17. Rassen JA, Choudhry NK, Avorn J, Schneeweiss S. Cardiovascular outcomes and mortality in patients using clopidogrel with proton pump inhibitors after percutaneous coronary intervention or acute coronary syndrome. Circulation 2009; 120: 2322-2329.
18. Kiyota Y, Schneeweiss S, Glynn RJ, Cannuscio CC, Avorn J, Solomon DH. Accuracy of Medicare claims-based diagnosis of acute myocardial infarction: estimating positive predictive value on the basis of review of hospital records. Am Heart J 2004; 148: 99-104.
19. Hanley GE, Morgan S, Hurley J, Van Doorslaer E. Distributional consequences of the transition from age-based to income-based prescription drug coverage in British Columbia, Canada. Health Econ 2008; 17: 1379-1392. 10.1002/hec.1337
20. Law MR, Wald NJ, Rudnicka AR. Quantifying effect of statins on low density lipoprotein cholesterol, ischaemic heart disease, and stroke: systematic review and meta-analysis. BMJ 2003; 326: 1423.
21. Choudhry NK, Levin R, Winkelmayer WC. Statins in elderly patients with acute coronary in typical practice syndrome: an analysis of dose and class effects. Heart 2007; 93: 945-951.
22. Plosker GL, Dunn CI, Figgitt DP. Cerivastatin: a review of its pharmacological properties and therapeutic efficacy in the management of hypercholesterolaemia. Drugs 2000; 60: 1179-1206.
23. Tu JV, Austin PC, Chan BT. Relationship between annual volume of patients treated by admitting physician and mortality after acute myocardial infarction. Jama 2001; 285: 3116-3122.
24. Choudhry NK, Anderson GM, Laupacis A, Ross-degnan D, Normand SL, Soumerai SB. Impact of adverse events on prescribing warfarin in patients with atrial fibrillation: matched pair analysis. BMJ 2006a; 332: 141-145.
25. Choudhry NK, Soumerai SB, Normand SL, Ross-Degnan D, Laupacis A, Anderson GM. Warfarin prescribing in atrial fibrillation: the impact of physician, patient, and hospital characteristics. Am J Med 2006b; 119: 607-615. S0002-9343(05)00911-3 [pii] 10.1016/j.amjmed.2005.09.052 [doi]
26. Kulik A, Levin R, Ruel M, Mesana TG, Solomon DH, Choudhry NK. Patterns and predictors of statin use after coronary artery bypass graft surgery. J Thorac Cardiovasc Surg 2007; 134: 932-938.
27. Block AE, Solomon DH, Cadarette SM, Mogun H, Choudhry NK, Patient and physician predictors of post-fracture osteoporosis management. J Gen Intern Med 2008; 23: 1447-1451.
28. Schneeweiss S, Seeger JD, Maclure M. Wang PS, Avorn J, Glynn RJ. Performance of comorbidity scores to control for confounding in epidemiologic studies using claims data. Am J Epidemiol 2001; 154: 854-864.
29. Krumholz HM, Brindis RG, Brush JE, et al. Standards for statistical models used for public reporting of health outcomes: an American Heart Association Scientific Statement from the Quality of Care and Outcomes Research Interdisciplinary Writing Group: cosponsored by the Council on Epidemiology and Prevention and the Stroke Council. Endorsed by the American College of Cardiology Foundation. Circulation 2006; 113: 456-462. CIRCULATIONAHA.105.170769 [pii] 10.1161/CIRCULATIONAHA.105.170769
30. Austin PC, Tu JV, Ko DT, Alter DA. Use of evidence-based therapies after discharge among elderly patients with acute myocardial infarction. CMAJ 2008; 179: 895-900. 179/9/895 [pii] 10.1503/cmaj.071481 [doi]
31. Hudson M, Richard H, Pilote L. Parabolas of medication use and discontinuation after myocardial infarction--are we closing the treatment gap? Pharmacoepidemiol Drug Saf 2007; 16: 773-785. 10.1002/pds.1414 [doi]